]> 2026-07-31T07:51:25+00:00 WBR0636 0 en Imipenem/cilastatin Cilastatin is used in combination with imipenem to inhibit the degradation of imipenem in the renal tubules by blocking renal dehydropeptidase 1. It has no synergistic activity with imipenem. Piperacillin/Tazobactam Since piperacillin is susceptible to penicillinase, tazobactam, an inhibitor of penicillinase (beta-lactamase) is administered in combination to increase the efficacy of the drug. Although the mechanism is synergistic, it does not act on a combined pathway. Pyrimethamine/leucovorin Leucovorin is usually co-administered with pyrimethamine to decrease the risk of myelosuppression. It has no synergistic activity. Izoniazid/Rifampin Izoniazid acts by inhibiting mycolic acid synthesis while rifampin inhibits the DNA dependent RNA polymerase. They do not act synergistically at the same pathway. Quinupristin/Dalfopristin Quinupristin and Dalfopristin act synergistically to inhibit protein synthesis by inhibiting both peptide bond formation and translocation. Pharmacology A new antibiotic agent is being studied for the treatment of multi-drug resistant gram-positive infection. The pharmaceutical company responsible for creating this drug explains that its mechanism of action involves 2 separate molecules that act synergistically at the same pathway. Which of the following combinations has a similar mechanism of action? E Infectious Disease 2020-10-28T01:16:27Z 2459150.5530903 WBR0636